Project Grant R37CA292711
Award Date
7/7/25
Completion Date
5/31/30
Dollars Obligated
$370K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Alabama, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) supports research to understand how cancer stem cells can transfer their mitochondria to macrophages, and how this mitochondrial transfer can reprogram the macrophages to support cancer growth and spread. The $161,794 award to Texas Tech University System will test the reproducibility of this mitochondrial transfer process across different cancer types, and determine if it is an active or passive...
This $895,779 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to advance the science of brain metastases from HER2-positive breast cancer. The key products and services to be delivered under this 7-year grant include: Understanding the fundamental biology and genetic risk factors of HER2-positive breast cancer metastases to the brain through patient tissue-based research. Developing real-time visualization techniques to track cancer cells and...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $676,584.00 to The University of Texas MD Anderson Cancer Center to conduct research on the co-evolution of cancer subclones and their tumor microenvironment in metastatic triple-negative breast cancer (MTNBC). The overarching goal is to expand the fundamental understanding of MTNBC metastasis by investigating the genomic and transcriptomic evolution of primary tumor cells and their...
This Cooperative Agreement award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $639,882 to the University of North Carolina at Chapel Hill to conduct research aimed at elucidating the molecular mechanisms underlying metastasis organ tropism in breast cancer. The project will utilize a comprehensive dataset of human primary and metastatic tumor samples, as well as genetically engineered mouse models, to identify the molecular determinants driving lung and...
This $544,475 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) aims to develop an in vitro cancer metastasis model system using decellularized organ-specific tissue (biomatrices) to study organ-specific cancer metastasis. The University of Texas Southwestern Medical Center, the awardee, hypothesizes that the biomatrices can recapitulate the organ microenvironment and enable the growth of organ-specific tumor colonies, which can be used to investigate...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Biology Research program (CFDA 93.396), provides $442,236 to the University of Alabama at Birmingham (UAB) from January 1, 2025 through December 31, 2029. The funding supports research to uncover a novel melanoma metastasis pathway driven by the YTHDF1 RNA-binding protein, and to evaluate therapeutic targeting of the IMPDH1 and TRKB/BDNF pathways that mediate this process. The research utilizes...
The National Cancer Institute (NCI) awarded a $220,018 Project Grant under the Cancer Treatment Research Program (CFDA 93.395) to the University of Louisville. The grant will fund research to determine whether chemotherapy-induced changes in mitochondrial function and dynamics in hematopoietic stem and progenitor cells (HSPCs) contribute to the development of pro-metastatic myeloid cells. The study aims to investigate the role of mitochondrial reactive oxygen species (ROS) production and...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the University of Pittsburgh aims to discover and validate compounds that can block cancer-mesenchymal stem cell (MSC) engulfment, as well as unravel the role of this engulfment process in breast cancer metastasis. The $180,632 award, effective May 1, 2025 through April 30, 2027, will support the development of a high-throughput microfluidic cell pairing platform to screen over 2,700...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $700,690 to Health Research, Inc. at Roswell Park Comprehensive Cancer Center to decipher the molecular mechanisms underlying breast cancer bone metastasis. The overarching goals are to understand how the transcriptional coactivators YAP/TAZ drive the progression of microscopic to established bone metastases, and to identify new therapeutic targets to treat both early and advanced...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $531,379 to the University of California, Los Angeles (UCLA) to investigate mitochondrial networks as a critical determinant of response to antibody drug conjugates (ADCs) in advanced/metastatic non-small cell lung cancer (NSCLC). The 5-year project aims to profile mitochondrial network structure and function in NSCLC cell lines, xenografts, patient-derived xenografts, and patient tumor...